Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia

NCT02827617 · clinicaltrials.gov ↗
COMPLETED
Status
56
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Oncology Institute of Southern Switzerland